Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Double-blinded, Randomized, Placebo-controlled Study for COVID-19 and Influenza Virus-Elicited Acute Respiratory Distress Syndrome (ARDS) Using Lomecel-B

NCT04629105 is registered in ClinicalTrials.gov with Longeveron Inc. as lead sponsor.

NCT NCT04629105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04629105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Double-blinded, Randomized, Placebo-controlled Study for COVID-19 and Influenza Virus-Elicited Acute Respiratory Distress Syndrome (ARDS) Using Lomecel-B
Lead sponsor
Longeveron Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
July 24, 2020
Completion date
July 31, 2025
Enrollment
70 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ards, human, covid19